Eli Lillys orforglipron (Foundayo) was the oral GLP-1 used in recent research showing that it can help to maintain weight loss after using an injectable
Semaglutide, the active ingredient in Ozempic and Wegovy, and tirzepatide, the active ingredient in Mounjaro and Zepbound, have shifted this paradigm
For individuals weighing Mounjaro vs Zepbound differences regarding cost, mechanism, and insurance coverage, those opting for tirzepatide for weight management find Zepbound supported by most insurance plans, given its dedicated role in weight loss
As with any IV therapy, vascular access, strict sterility, and the small but real possibility of an allergic or anaphylactic reaction apply
CagriSema is not yet FDA-approved in the United States